About
Our Impact
During the first four measurement years of the Rise to Immunize® (RIZE) campaign, participating groups documented or administered a total of 28,266,988 vaccines. View more details on our progress in the RIZE infographic!
The breakdown by measurement year and vaccine are as follows:
| Measurement Year | Influenza (19+) | Pneumococcal (66+) | Td/Tdap (19+) | Zoster (50+) | RSV (75+) | COVID (19+) | Hep B (19-59) | Total by Measurement Year |
| 2021 (Q3 2021 – Q2 2022) |
4,422,559 | 214,982 | 710,326 | 600,612 | - | - | - | 5,948,479 |
| 2022 (Q3 2022 – Q2 2023) |
4,926,623 | 299,926 | 819,573 | 614,850 | - | - | - | 6,660,972 |
| 2023 (Q3 2023 – Q2 2024) |
4,805,823 | 288,857 | 854,570 | 615,272 | - | - | - | 7,682,743 |
| 2024 (Q3 2024 – Q2 2025) |
4,505,936 | 221,265 | 886,940 | 473,008 | 52,998 | 1,628,209 | 206,438 | 7,974,794 |
| Total by Vaccine | 18,660,941 | 1,025,030 | 3,271,409 | 2,303,742 | 52,998 | 1,628,209 | 206,438 | 28,266,988 |
Over the course of four measurement years, there was an 8.8 percent improvement in the bundle measure (66+ vaccinated with influenza, pneumococcal, Td/Tdap, and zoster), which equates to 351,321 additional adults receiving comprehensive immunization care.
The RIZE campaign presented a poster on campaign impact and lessons learned at the CDC's 2024 National Immunization Conference in Atlanta.
Due to our impact on influenza vaccination rates across the country, the National Influenza Immunization Summit recognized RIZE as a National Winner of their 2023 “Influenza Season” Immunization Champion Award.